Published customer image:
Rabbit Complement (C12CC) used as asource of complement in a complemnt dependent cytotoxicity assay on T-cell prolymphocytic leukemia cells.
Image caption:
Anti-CCR7 mAb mediates a strong CDC on T-PLL cells. a CDC on alemtuzumab-naïve patients. Leukemic cells from T-PLL patients (n = 8) were incubated with anti-CCR7, anti-CD52 (alemtuzumab), or an IC at the indicated concentrations and then exposed to rabbit complement for 1.5 h. The percentage of specific cell lysis was determined through quantification of 7-AAD incorporation by flow cytometry. b CDC on alemtuzumab-refractory patients. Specific lysis on T-PLL cells from 4 refractory patients was assayed as described in A.

From: Cuesta-Mateos C, et al.
CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia.
Biomark Res. 2020 Oct 24;8:54.
doi: 10.1186/s40364-020-00234-z.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.